Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years~* Type 2 Diabetes Mellitus~* Hemoglobin A1c \< 10%~* Stable diabetes therapy~* Must be on maximally tolerated dose of statin of at least moderate Intensity~* Fasting triglycerides ≤ 600 mg/dL~* Not at LDL-C or Non-HDL-C goal.~Exclusion Criteria:~* Moderate to severe renal dysfunction~* Uncontrolled hypertension~* Persistent active liver disease or hepatic dysfunction~* Has taken a cholesterylester transfer protein inhibitor in the last 12 months,~* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
- Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).